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Abstract 
Opioid Free Anesthesia (OFA) is emerging as a new stimulating research perspective. The 
rationale to propose OFA is based on the aim to avoid the negative impact of intraoperative 
opioid on patient’s postoperative outcomes and also on the physiology of pathways involved 
in intraoperative nociception. It is based on the concept of multimodal anesthesia. OFA has 
been shown to be feasible but the literature is still scarce on the clinically meaningful benefits 
for patients as well as on the side effects and / or complications that might be associated with 
it. This review focused first on the physiology of nociception, the reasons for using or not 
opioids during anesthesia, and then on the literature reporting evidence-based proofs of 
benefits / risks associated with OFA. 
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Practice points: 
• OFA is a multimodal anesthesia associating drugs and/or techniques that allows a good 
quality general anesthesia with no need for opioids 
 2 
• Anti-nociception during general anesthesia can be obtained by interfering with various 
neuromediators not only by interfering with enkephalins with opioids 
• Studies have shown that OFA allows a postoperative morphine sparing, PONV reduction 
and a trend towards a reduction of opioid-related adverse events 
 
 
 
Introduction 
Opioid-free anesthesia (OFA) has become more and more popular amongst 
anesthesiologists around the world. It is an emerging technique and a recent research 
perspective based on the idea that avoiding intraoperative opioids would be associated with 
better postoperative outcomes. Indeed, opioids have shown their limits, and reducing opioids 
administration ered, at any time during the perioperative period, has been proposed for many 
years in the literature. Thus, multimodal postoperative analgesia has been the gold standard 
for more than 25 years [1]. It allows opioid-sparing and better outcomes than morphine 
administered as a sole analgesic agent after surgery.  OFA is based on the same concept, 
as one drug will not replace opioids. It is the association of drugs and/or techniques that 
allows a good quality general anesthesia with no need for opioids. The association can 
combine NMDA antagonists (ketamine, lidocaine, magnesium sulfate), sodium channel 
blockers (local anesthetics (LA)), anti-inflammatory drugs (NSAID, dexamethasone, LA) and 
alpha-2 agonists (dexmetedomidine, clonidine). Of course, for toxicity reasons all these 
drugs / techniques will not be administered simultaneously to the same patient. Moreover, all 
these drugs have documented side effects. The idea of OFA is very exciting! However, the 
literature remains scare on the subject. Many retrospective, case reports or single-physician 
experience, are available today but only few well-designed studies bringing evidence-based 
proofs of the benefits of OFA for the patients, have been published so far. This is why this 
review will first focus on the principles and physiology on which OFA is based on, then it will 
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detail what is known so far on how to perform OFA and finally report the evidence-based 
proofs of benefits / risks associated with it.  
 
Why do we use intraoperative opioids? 
 
 Anesthesia textbooks published in the last 50 years have an identical first paragraph on the 
concerning the use of opioids during anesthesia with a double objective: the objective is 
twofold: 1) to reduce the need for hypnotic agents and 2) to ensure effective analgesia. The 
introduction of synthetic morphine in the 1960s revolutionized changed anesthesia’s practice 
by allowing savings in hypnotic agents consumption and inhibiting on of the sympathetic 
system without cardiovascular collapse or histamine release. With regard to analgesia, the 
aim is to limit the reaction to nociceptive stimuli and in particular to ensure the control of the 
resulting cardiovascular reactions [2]. Synthetic opioids were therefore widely adopted as 
soon as they appeared to limit the effects of hypnotic agents available at the time, by 
reducing their doses, facilitatinge hemodynamic stability, reducinge cardiac output without 
reducing coronary perfusion, blocking spontaneous breathing and facilitatinge mechanical 
ventilation. By blocking the ascending nociceptive stimuli, opioids are indeed very effective. 
However, pain and nociception are two different things! Pain is indeed a conscious 
unpleasant perception of a noxious stimulus and nociception is the stimulation of noxious 
receptors.  Anti-nociception is then the suppression of the consequences of the stimulation of 
the noxious receptors. Nociception without pain is possible, i.e. under general anesthesia. 
What we routinely call “intraoperative analgesia” should indeed be called “intraoperative 
control of the consequences of the stimulation of noxious receptors” or “control of the 
autonomous nervous system response to nociception” [3].  Looking at the physiology, 
various mediators are involved in nociception pathways: serotonin, norepinephrine, 
enkephalin, peptides…etc. Anti-nociception can then be obtained by interfering with various 
neuromediators not only by interfering with enkephalins with opioids [4]. Then, opioids are 
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not indispensable essential for general anesthesia [3].   However, we are currently lacking 
accurate and validated monitoring to measure of intra-operative nociception [4]. 
 
Why reducing or avoiding opioids perioperatively? 
 
After decades of under-treatment of pain, the most recent audits have shown a clear 
progress over the last 20 years [5]. The systematic use of opioids contributed to this advance. 
However, this broad and high-dose use of opioids has revealed its limits: less efficacy on 
pain during movement, dose-dependent side effects, which can be very disabling for the 
patient and delay postoperative rehabilitation, dose-dependent hyperalgesia paradoxical 
source of acute and chronic pain, immunomodulation that may have a negative impact on 
infectious or cancerous pathologies [6] and finally, doubt about possible neurotoxicity [7].  
Moreover, anesthesiologists and perioperative opioids over prescriptions are part of the 
current so called ‘opioid crisis’ currently happening in North America [8,9]. Patients who were 
initially prescribed opioids to treat acute pain including pain after surgery transitioned to 
acquire their substance of abuse on the black market and often move on to use more 
affordable and available (but also more deadly) related street drugs [10]. Perioperative 
prescriptions have been incriminated [11] as well as opioid treatment for chronic pain. 
Anesthesiologists are also part of the problem [9]. The consequences are devastating with 
more than 60 000 US adult alleged to be dead from drug overdose in 2017 [12]. All these 
reasons explain the motivation to move away from opioids administration in the postoperative 
period but also during general anesthesia. Indeed, modern postoperative analgesia is based 
on opioid sparing. The principle of balanced analgesia described by Kehlet [1]  has been 
prevailing for more than 25 years. The prescriptions of combinations of analgesics of 
different classes and / or techniques of regional anesthesia are recommended to optimize 
analgesia pain control while limiting the adverse undesirable effects attributable to the 
different of each analgesic agents. The evolution of intraoperative anesthesia is comparable 
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similar. Indeed, it evolved from single agent anesthesia to opioid-based anesthesia and then 
multimodal or balanced anesthesia. Nowadays, balanced anesthesia without opioids (opioid-
free anesthesia (OFA)) is feasible [13]. While there are evidences evidence-based proofs are 
showing that OFA is associated with benefits for the patients (cf. below), proofs are lacking 
concerning “opioid-free anesthesia and analgesia (OFAA)” which includes the total 
perioperative period. OFAA is still a challenge today. Indeed, a dramatic reduction of 
intraoperative opioids is not always associated with a reduction of postoperative opioids [14]. 
However, according to Susan et al’ [15] hypothesis, the timing of administration of opioids is 
crucial: when administered during surgery (= tissue injury), opioids aggravate acute 
postoperative (= post-injury) pain, in contrast to their analgesic effect when given after 
surgery (= after tissue injury). The concept of OFA; i.e. no opioids during surgery, fits well 
with this theory. 
 
How to perform anesthesia without opioids? 
Opioid-free anesthesia is a multimodal anesthesia combining different drugs and / or 
techniques. Regional anesthesia/ analgesia is, of course, the best technique to reduce or 
avoid intraoperative opioids. Indeed, the blockage of nociceptive afferences is perfectly 
ensured by regional anesthesia/ analgesia and benefits have been long proven in the 
literature [16]. 
When regional anesthesia is not applicable, many other anesthetic drugs inhibit the 
sympathetic system and reduce the consumption of opioids perioperatively: 
- Intravenous lidocaine administered intravenously blocks sodium channels and discharges 
of peripheral neurons excited by nociceptive stimuli, inhibits NMDA receptors and has anti-
inflammatory properties. All these effects are clinically translated into an analgesic benefit, 
morphine sparing, a decrease in length of stay, an earlier resumption of transit, a reduction in 
the incidence of nausea and vomiting and a faster postoperative rehabilitation [17]. This has 
been shown in different types of surgery (abdominal but also spine surgery) [18]. 
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- By antagonizing NMDA receptors, ketamine prevents postoperative hyperalgesia. Several 
meta-analyzes have reported a beneficial effect of ketamine on the intensity of postoperative 
pain, the reduction of opioid consumption per and postoperatively and the reduction of 
chronic pain after surgery [19]. Ketamine is also helpful in reducing intraoperative blood 
pressure variability [20].  
- Magnesium sulfate is a noncompetitive antagonist of NMDA receptors by inhibition of 
intracellular calcium flow. Evidences are lacking, but some studies have shown morphine 
sparing when magnesium is administered intraoperatively [21]. Moreover, a recent meta-
analysis reported that magnesium significantly reduces intraoperative heart rate variability 
[20].  
- Anti-inflammatory drugs (dexamethasone and NSAIDs) are also helpful when avoiding 
opioids. NSAIDs allow a savings of spare about 50% in morphine, which results resulting in a 
reduction in PONV, sedation and duration of postoperative ileus, as well as an improvement 
in pain scores compared with morphine alone. This morphine savings is the most interesting 
when compared to other non-morphine analgesics used in current practice (nefopam, 
paracetamol) Morphine sparing effect of NSAIDs is more important than the one of 
paracetamol and nefopam [22].  With regard to dexamethasone, there are now numerous 
studies showing morphine savings associated with a reduction in PONV and fatigue and 
better postoperative rehabilitation with the doses recommended for the prevention of nausea 
and vomiting; i.e. 8 mg. The single dose administered at the beginning of the procedure (0.1 
mg / kg) thus allows both a prevention of PONV and an analgesic benefit  [23]. 
- Drugs ensuring hemodynamic stability: 
Opioids have been used because they provide a good hemodynamic stability. It has been 
shown several times that intraoperative hemodynamic instability is associated with increased 
postoperative morbidity. Therefore, as P Forget stated [20], any strategy oriented to reduce 
the use of opioids should also minimize the sympathetic response triggered by surgery. 
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Alpha-2 agonists (clonidine, dexmedetomidine (Dex)) have been proposed to ensure this 
stability. They allow a direct sympathetic blockade. Thanks to their pharmacological 
characteristics (sedation, hypnosis, anxiolysis, sympatholysis and analgesia), they are 
interesting adjuvants to multimodal analgesia / anesthesia. Their antinociceptive effects are 
attributed to the stimulation of alpha-2 adrenergic receptors located in the central nervous 
system. The analgesic, anti-emetic and anxiolytic properties of clonidine are well known [24]. 
Its use could be limited because of a long delay of action (20 minutes) and a prolonged half-
life (15 hours). Dexmedetomidine is a more selective agonist of alpha-2 receptors. Its delay 
of action is shorter (6 minutes) and its half-life shorter (2 hours) are shorter than those of 
clonidine. In terms of side effects, both drugs are associated with risks of hypotension and 
bradycardia [25]. Meta-analysis have shown that clonidine and dexmedetomidine Dex 
provide induce morphine sparing, analgesia with and PONV reduction [26,27]. The morphine 
savings of dexmedetomidine Dex were 3 times greater than that of clonidine [26]. This was 
not associated with sedative effects delaying postoperative rehabilitation. However, the use 
of dexmedetomidine Dex was associated with a higher risk of postoperative bradycardia. The 
clinical relevance and consequences of this side effect are hardly appreciable because none 
of the studies included in the meta-analysis reported major adverse events. In addition, the 
definition of bradycardia is unclear in all studies. When comparing intravenous anesthesia 
with propofol – dexmedetomidine - lidocaine with propofol – remifentanil, in laparoscopic 
cholecystectomies, patients receiving remifentanil were experiencing experienced more 
bradycardia than those in the dexmedetomidine Dex group [28]. However, some studies 
have chosen to study OFA with dexmedetomidine Dex with the objective of hemodynamic 
stability and controlled hypotension [29,30]. While some studies were negative [31], most 
studies reported a good hemodynamic stability with often bradycardia and hypotension with 
dexmedetomidine Dex (which were the objectives in these studies)  [32,33]. This limitation to 
the systematic use of dexmedetomidine Dex requires further studies whose main objective 
will be the evaluation of side effects and their clinical consequences. 
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Beta blockers (BB) have also been proposed to ensure hemodynamic stability during OFA 
[34,35]. Studies and meta-analysis have reported benefits in reducing intraoperative and 
postoperative opioids and PONV. However, the literature is scarce on the subject (BB used 
during an OFA) and perioperative administration of beta blockers is associated with specific 
side effects including a doubt in increasing the risk of stroke [36]. 
 
What are the benefits of OFA? 
The isolated administration of the previously presented drugs does not allow to perform 
anesthesia without opioids. None of the drugs introduced before allows by one-self 
performing anesthesia without opioids. However, their association with modern techniques of 
anesthesia and surgery is an alternative to the use of opioids. Hanci et al [37] compared 
intubation conditions during lidocaine and propofol-associated anesthesia with 
dexmedetomidine Dex or fentanyl. The intubation conditions were better in the 
dexmedetomidine Dex group. They reported more bradycardia (lower low limit: 60 bpm) in 
the dexmedetomidine Dex group and more hypotension in the fentanyl group, with no major 
adverse effects events reported. Another older study compared dexmedetomidine Dex and 
fentanyl during an inhaled desflurane anesthesia for bariatric surgery [38]. For a comparable 
depth of anesthesia monitored by BIS, dexmedetomidine The Dex allowed desflurane 
savings for an identical depth of anesthesia measured by BIS, a morphine saving and better 
analgesia. OFA has been shown Morphic sparing with OFA was shown to result in a 
significant reduction in PONV: Ziemann-Gimmel et al [39] demonstrated a 17% reduction in 
the risk of PONV by comparing an intravenous anesthesia combining propofol- 
dexmedetomidine Dex -ketamine with an inhaled anesthesia with opioids. More recently, 
Mulier et al reported, in a small randomized controlled trial RCT (n = 50) the benefits of 
modern OFA (propofol, rocuronium, dexmedetomidine Dex, lidocaine, ketamine) when 
compared with OBA (propofol, rocuronium, sufentanil) during bariatric surgery [40]. OFA was 
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associated with a better recovery, better comfort (QoR-40 score), reduced postoperative pain 
while consuming less postoperative morphine, reduced PONV and less postoperative 
oxygen desaturation. In a second publication study [41], performed in they retrospectively 
reported in 9246 patients who underwent bariatric surgery, they retrospectively reported that 
OFA was associated with less postoperative complications. Meta-analysis have also reported 
benefits with OFA  [42, 43,44]. However, results have to be analyzed with caution as the 
heterogeneity of the studies included was high (i.e. 83 % in Frauenknecht et al [42]). In 
addition, and all these meta-analysis included some studies in which dexmedetomidine Dex 
was administered as the same time as opioids. More well-designed large-scale studies are 
definitely needed required to further document show the benefits of OAF for the patients. 
There are currently 14 on going trials registered on clinical trial.gov on this topic. 
 
Are there specific indications for OFA? 
 
Patients who can benefit from this type of anesthesia OFA are those who are most sensitive 
to deleterious side effects of opioids. Obese patients and patients suffering from respiratory 
insufficiency are, of course, crossing mind firstly the first to come to mind. Morphine 
administration is associated with an abnormal respiratory cycle (alternating respiratory 
depression with airway obstruction) [45]. This is accentuated and aggravated in obese 
patients with sleep apnea syndrome [45]. Thus, part of the studies showing the interest of 
dexmedetomidine Dex perioperatively, were made performed in obese patients [43]. Several 
clinical cases and studies have described the benefit of morphine-free anesthesia with 
dexmedetomidine Dex in super-obese patients (BMI> 50 kg / m2) (22,23). Other studies are 
obviously needed to evaluate the real benefit of opioid-free anesthesia in these patients. It 
can also be assumed that OFA would be beneficial in patients with respiratory insufficiency 
or obstructive bronchopneumopathy.  Data are missing to date to validate these indications. 
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Another subgroup of patients suffering from chronic pain and / or consuming opioids before 
surgery, would be another subpopulation that could benefit the most from OFA. These 
patients are at higher risk of more intense severe postoperative acute pain while consuming 
more postoperative opioids [46]. It has been shown that all this increases the risk of post-
surgical pain chronicization  [46]. One could hypothesize that reducing the activation of 
NMDA receptors and therefore opioid-induced hyperalgesia by avoiding intraoperative 
opioids could reduce postoperative acute and chronic pain and opioid needs in these 
patients. However, no data are currently available to confirm this hypothesis. 
 
The question also arises for oncological cancer surgery (see chapter on postoperative pain 
after cancer). The Opioids impair cell proliferation, inflammation, angiogenesis and the 
immune response. This could participate in the evolution of the tumor. However, the 
interactions and cellular mechanisms involved in the role played by opioids in cancer 
recurrence are complex and far from fully understood, as the pain itself is 
immunosuppressive [47]. Clinical data on the potential implication of opioids on cancer 
recurrence are contradictory. No evidence-based proofs are available today to formally 
suggest that opioids should be avoided during surgery for cancer. 
 
Finally, intuitively, one could suggest that the more painful and the longer the surgery, the 
bigger greater the impact of opioid-sparing strategies would be. However, well-designed 
RCTs are needed to confirm this suggestion. 
 
Unanswered questions and future research agenda  
OFA is a multimodal anesthesia and therefore consist of a combination of multiple drugs. 
Many institutions have their own ‘cocktail’, some of them are even published [48]. However, 
as presented above, the proofs of the benefits of such combinations of multiple drugs are still 
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scarce in the literature [12]. ‘Cocktails’ published without any evidence-based proof of a 
positive balance of benefits over risks should not be recommended. Moreover, the doses of 
each of the drugs included in the ‘cocktail’ are also not clearly defined especially for 
dexmedetomidine Dex. As presented shown in table 1, doses vary from one study to another, 
and no formal recommendation can be formulated. The optimal dose of dexmedetomidine 
Dex allowing benefits with acceptable risks of bradycardia and hypotension has not been 
determined yet. 
As stated by P Lavand’homme in a recent editorial [13], there is an urgent need to develop 
accurate monitoring of intraoperative nociception.  
Finally, most publications on OFA involved patients undergoing bariatric surgery. There is a 
lack of studies showing benefits in other types of surgery. Procedure-specific studies and 
protocols are needed.  
 
Conclusion  
 
Some authors present opioid-free anesthesia as a new paradigm that will revolutionize and 
change our practices in the years to come. While it is true that multimodal anesthesia like 
multimodal analgesia has shown benefits, studies and data are lacking. In terms of benefits, 
OFA has never been studied with modern monitoring of intraoperative analgesia. Evidence-
based proofs of short and long-term benefits of OFA as well as well documented 
intraoperative protocols are still yet to come. 
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Legends of the tables: 
Table 1: 
Randomized controlled trials comparing opioid-free anesthesia using dexmetedomidine vs 
opioid-based anesthesia. LOS: length of stay; HR: heart rate; MBP: mean blood pressure 
Dex: dexmetedomidine; NS:  non-statistically significant; NA: non-applicable.  
References n Doses of Dex Surgery Results in Dex group Bradycardia (lowest 
HR)
Hypotension (lowest 
MBP)
Feld,  2006 (38) 20 0.5 mcg/kg + 0.4 mcg/kg/h vs fentanyl Bariatric Pain reduction HR (60), MBP (60). HR 
and MBP lower with Dex
Turgut, 2008 (49) 50 0.6 mcg/kg + 0.2 mcg/kg/h vs fentanyl spine PONV reduction
Delayed rescue analgesia
HR (70): NS
More hypotension with 
dex
Tufanogullari, 
2008 (50)
80 0.2 vs 0.4 vs 0.8  mcg/kg/h vs saline Bariatric Reduction in postop morphine 
consumption, anti-emetics and 
PACU LOS
HR (60), MBP (60). More 
hypotension with Dex
Hanci, 2010 (37) 60 Bolus 1 mcg/kg vs fentanyl intubation OFA better HR (60), MBP (60). HR 
lower with dex
Olutoye, 2010 
(51)
109 0.75 or 1 mcg/kg  vs morphine Tonsillectomy 
(children)
NS No bradycardia
Jung, 2011 (52) 50 1 mcg/kg + 0.2-0.7 mcg/kg/h vs 
remifentanil in PACU
hysterectomy More sedation with Dex FC: NS
Zieman-Grimmel, 
2014(39)
124 0.5 mcg/kg + 0.1-0.3 mcg/kg/h vs 
fentanyl
Bariatric PONV reduction Bradycardia: NS
Cifti, 2015 (53) 70 Bolus 1 mcg/kg  vs remifentanil (bolus) intubation during 
mandibular fracture
Pain: NS. Dex=less desaturation NS
Hwang, 2015 (54) 40 0.01-0.02 mcg/kg/min vs remifentanil spine Reduction in postoperative:  pain, 
rescue analgesia, PONV
NA
Bakan, 2015(28) 80 0.6 mcg/kg + 0.3 mcg/kg/h vs fentanyl cholecystectomy Reduction in postoperative: pain, 
morphine consumption
HR and FC lower with 
remifentanil
Choi EK, 2017 
(55)
80 1 mcg/kg + 0.3-0.5 mcg/kg/h vs 
remifentanil
thyroidectomy Reduction in PONV. delayed 
extubation, prolonged PACU LOS
HR (60), MBP (60). HR 
and MBP lower with Dex
Mullier, 2018 (40) 50 0.5 mcg/kg + 0.25-1 mcg/kg/h vs 
sufentanil
Bariatric Reduction in postoperative: 
desaturation,  PONV, pain and 
NS
